sarepta nasdaq - Search News

News

Sarepta Therapeutics, FDA and Elevidys

Sarepta shares drop after EU regulators reject Elevidys gene therapy

Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Elevidys,

· 1d · on MSN

Sarepta drops as report suggests FDA needs new trials for Elevidys

EconoTimes · 8h

FDA Probes Death of 8-Year-Old Linked to Sarepta’s Elevidys Gene Therapy

2don MSN

Arrowhead expects Sarepta to honor financial obligations

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced Wednesday that it expects its partner Sarepta Therapeutics (NASDAQ:SRPT), ...

1don MSN

Sarepta Therapeutics (SRPT): “They Should Be Prosecuted,” Says Jim Cramer

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.

Sarepta Therapeutics stock tumbles on concern about FDA study requirements

According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...

2don MSN

Sarepta cut to Underperform at BofA on Elevidys concerns

Bank of America downgraded Sarepta Therapeutics (NASDAQ:SRPT) to Underperform from Neutral on Wednesday, becoming the latest ...

3don MSN

Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns

We recently published 10 Big Names Get Slammed. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the biggest losers on ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results